Every material Form 8-K Verrica Pharmaceuticals Inc. has filed with the SEC since May 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Verrica Pharmaceuticals reported second-quarter 2026 results on August 6, 2026. Total revenue fell to $5.9 million from $12.7 million a year earlier, and the company posted a net loss of $13.2 million compared with net income of $0.2 million, even though U.S. YCANTH product revenue rose. The company also announced a credit facility of up to $27.5 million with an entity controlled by its chairman and largest shareholder, which it says could extend its cash runway into 2028.
Total revenue was $5.9 million versus $12.7 million in Q2 2025, which included $8.0 million of one-time Torii milestone revenue in the prior year.
U.S. YCANTH net product revenue was $5.1 million, up from $4.5 million, with dispensed applicator units up about 46% year over year to 19,626.
Q2 2026 net loss was $13.2 million, or $0.62 per share, versus net income of $0.2 million, or $0.02 per share, in Q2 2025.
Cash was $11.2 million at June 30, 2026, down from $30.1 million at December 31, 2025; the credit facility is up to $27.5 million with an entity controlled by Paul B. Manning.
At its June 5, 2026 annual meeting, Verrica Pharmaceuticals stockholders approved the Amended and Restated 2018 Equity Incentive Plan, which took effect immediately, and re-elected two directors. The filing shows all proposals passed, with shareholder votes on the equity plan and executive pay drawing more opposition than the other items.
Stockholders approved the Amended and Restated 2018 Equity Incentive Plan, with 11,142,881 votes for and 433,852 against
Paul B. Manning and Lawrence Eichenfield were elected as directors to serve until the 2029 annual meeting
Stockholders ratified KPMG LLP as the independent registered public accounting firm for fiscal 2026 with 14,058,234 votes for
14,069,331 shares, or 81.89% of the 17,178,786 shares outstanding on the record date, were present or represented at the meeting
Verrica Pharmaceuticals reported first quarter 2026 total revenue of $5.0 million, up from $3.4 million a year earlier, with U.S. YCANTH net product revenue of $4.3 million. The net loss was $9.7 million, or $0.45 per share, compared with $9.7 million, or $1.03 per share, in the first quarter of 2025, and cash fell to $20.6 million at March 31, 2026 from $30.1 million at December 31, 2025.
Total revenue was $5.0 million versus $3.4 million in Q1 2025; U.S. YCANTH net product revenue was $4.3 million versus $3.4 million.
Net loss was $9.7 million, or $0.45 per share, versus $9.7 million, or $1.03 per share, in Q1 2025.
Non-GAAP net loss was $8.8 million, or $0.41 per share, versus $8.3 million, or $0.88 per share, a year earlier.
Cash was $20.6 million at March 31, 2026, down from $30.1 million at December 31, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Verrica Pharmaceuticals Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →